Goldman Sachs Group Analysts Give GlaxoSmithKline (GSK) a GBX 1,900 Price Target
Other research analysts also recently issued research reports about the stock. Jefferies Financial Group set a GBX 1,775 ($23.19) target price on shares of GlaxoSmithKline and gave the company a buy rating in a research report on Thursday, August 16th. Liberum Capital reissued a buy rating and issued a GBX 1,630 ($21.30) price objective on shares of GlaxoSmithKline in a research report on Wednesday, August 15th. Shore Capital reissued a buy rating on shares of GlaxoSmithKline in a research report on Wednesday, August 15th. Berenberg Bank reissued a buy rating and issued a GBX 1,790 ($23.39) price objective on shares of GlaxoSmithKline in a research report on Thursday, August 23rd. Finally, BNP Paribas set a GBX 1,750 ($22.87) price objective on shares of GlaxoSmithKline and gave the company a buy rating in a research report on Tuesday, September 11th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of GBX 1,512.99 ($19.77).
GlaxoSmithKline stock opened at GBX 1,439.20 ($18.81) on Monday. GlaxoSmithKline has a 1-year low of GBX 1,235.20 ($16.14) and a 1-year high of GBX 1,724.50 ($22.53).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: Is it better to buy a fund with a higher or lower NAV?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.